Funding

Developing innovative medical devices, and especially new drug development, is considered a high-risk investment requiring lengthy processes and significant capital.
Institutional investors, such as venture capital funds and specialized investment firms, typically prefer to invest at later stages of a venture—after clinical trials, regulatory approvals, or even at the commercialization stage.

Private investors, on the other hand, tend to focus on sectors with lower risk and a significantly faster return on investment.
This situation creates an investment gap at the early stages of startups, making it difficult for many young companies to secure funding.